Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: The hematological experience

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Liseth, Knut ^a   Ersvr, Elisabeth ^a   Hervig, Tor ^a   Bruserud, Øystein ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; DNA VACCINE; DOCETAXEL; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; KEYHOLE LIMPET HEMOCYANIN; LIPOSOME; MONTANIDE ISA 51; PEPTIDE PR1; PEPTIDE RHAMM R3; PEPTIDE VACCINE; PLERIXAFOR; RAPAMYCIN; STEM CELL FACTOR; UNCLASSIFIED DRUG; WT1 PROTEIN; ZINC FINGER PROTEIN; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CYTOTOXICITY; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; REVIEW; T LYMPHOCYTE; ANIMAL; BLOOD DISEASE; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; T-LYMPHOCYTES;

EID: 77954560509     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/692097     Document Type: Review

References (137)

1. Keilholz U., Letsch A., Busse A., A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS Blood 2009 113 26 6541 6548
2. Molldrem J. J., Lee P. P., Wang C., Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nature Medicine 2000 6 9 1018 1023
3. Oka Y., Tsuboi A., Taguchi T., Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proceedings of the National Academy of Sciences of the United States of America 2004 101 38 13885 13890
4. Smith A., Wisloff F., Samson D., Guidelines on the diagnosis and management of multiple myeloma 2005 British Journal of Haematology 2006 132 4 410 451
5. Liseth K., Abrahamsen J. F., Ekanger R., Nesthus I., Sjo M. S., Survival after high-dose therapy with autologous stem cell support Tidsskrift for den Norske Laegeforening 2004 124 10 1374 1375 (Pubitemid 40331770)
6. Porrata L. F., Litzow M. R., Tefferi A., Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia Leukemia 2002 16 7 1311 1318
7. Porrata L. F., Markovic S. N., Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation Clinical and Experimental Medicine 2004 4 2 78 85
8. Porrata L. F., Gertz M. A., Inwards D. J., Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma Blood 2001 98 3 579 585
9. Parkman R., Cohen G., Carter S. L., Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation Biology of Blood and Marrow Transplantation 2006 12 9 919 927
10. Kim D. H., Sohn S. K., Won D. I., Lee N. Y., Suh J. S., Lee K. B., Rapid helper T-cell recovery above 200 106 /l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation Bone Marrow Transplantation 2006 37 12 1119 1128
11. Ersvr E., Zhang J.-Y., McCormack E., Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients European Journal of Haematology 2007 79 3 210 225
12. Behl D., Porrata L. F., Markovic S. N., Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia Leukemia 2006 20 1 29 34
13. Bruserud O., Ulvestad E., Berentsen S., Bergheim J., Nesthus I., T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation Scandinavian Journal of Immunology 1998 47 1 54 62 (Pubitemid 28057352)
14. Bruserud O., Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells International Journal of Immunopharmacology 2000 22 1 69 81
15. Ersvr E., Hampson P., Wendelbo O., Lord J. M., Gjertsen B. T., Bruserud O., Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex Hematology 2007 12 3 199 207
16. Ersvr E., Hampson P., Hatfield K., T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon- that can be further increased by a novel protein kinase C agonist PEP005 Cancer Immunology, Immunotherapy 2007 56 6 913 925
17. Olsnes A. M., Ryningen A., Ersvr E., Bruserud O., In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22 Journal of Interferon and Cytokine Research 2008 28 5 297 310
18. Olsnes A. M., Ersvr E., Ryningen A., Bruserud O., Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors Hematology 2008 13 6 329 332
19. Mackall C. L., Fleisher T. A., Brown M. R., Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy Blood 1997 89 10 3700 3707
20. Crooks G. M., Weinberg K., Mackall C., Immune reconstitution: from stem cells to lymphocytes Biology of Blood and Marrow Transplantation 2006 12 supplement 1 42 46
21. Karl J. C., Mackall C. L., Cancer therapy-induced immune modulation Cancer Chemotherapy and Biological Response Modifiers 2005 22 325 341
22. Mackall C. L., Helman L. J., High-dose chemotherapy for rhabdomyosarcoma: where do we go from here Journal of Pediatric Hematology and Oncology 2001 23 5 266 267
23. Mackall C. L., T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review Stem Cells 2000 18 1 10 18
24. Ashihara E., Shimazaki C., Yamagata N., Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis Bone Marrow Transplantation 1994 13 4 377 381
25. Jimenez M., Ercilla G., Martinez C., Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens Leukemia 2007 21 8 1628 1637
26. Bruserud O., Kittang A. O., The chemokine system in experimental and clinical hematology. Current Topics in Microbiology and Immunology. In press
27. Salem M. L., Cole D. J., Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Cancer Immunology, Immunotherapy 2010 59 3 341 353
28. Socinski M. A., Cannistra S. A., Elias A., Antman K. H., Schnipper L., Griffin J. D., Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man The Lancet 1988 1 8596 1194 1198
29. Socinski M. A., Cannistra S. A., Sullivan R., Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo Blood 1988 72 2 691 697
30. Vellenga E., van Agthoven M., Croockewit A. J., Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study British Journal of Haematology 2001 114 2 319 326 (Pubitemid 32762230)
31. Vose J. M., Sharp G., Chan W. C., Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease Journal of Clinical Oncology 2002 20 9 2344 2352
32. Krbling M., Anderlini P., Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001 98 10 2900 2908
33. Smith T. J., Khatcheressian J., Lyman G. H., 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline Journal of Clinical Oncology 2006 24 19 3187 3205
34. Levesque J.-P., Takamatsu Y., Nilsson S. K., Haylock D. N., Simmons P. J., Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor Blood 2001 98 5 1289 1297
35. Korbling M., Huh Y. O., Durett A., Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1(dim)) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease Blood 1995 86 7 2842 2848
36. Copelan E. A., Ceselski S. K., Ezzone S. A., Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease Journal of Clinical Oncology 1997 15 2 759 765
37. Koc O. N., Gerson S. L., Cooper B. W., Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF Journal of Clinical Oncology 2000 18 9 1824 1830
38. Isidori A., Tani M., Bonifazi F., Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients Haematologica 2005 90 2 225 231 (Pubitemid 40293285)
39. Glaspy J. A., Shpall E. J., LeMaistre C. F., Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients Blood 1997 90 8 2939 2951
40. Shpall E. J., The utilization of cytokines in stem cell mobilization strategies Bone Marrow Transplantation 1999 23 supplement 2 S13 S19
41. Calandra G., McCarty J., McGuirk J., AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data Bone Marrow Transplantation 2008 41 4 331 338
42. Flomenberg N., Devine S. M., DiPersio J. F., The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone Blood 2005 106 5 1867 1874
43. Calandra G., Bridger G., Fricker S., CXCR4 in clinical hematology. Current Topics in Microbiology and Immunology. In press
44. Bensinger W., Appelbaum F., Rowley S., Factors that influence collection and engraftment of autologous peripheral-blood stem cells Journal of Clinical Oncology 1995 13 10 2547 2555
45. Goldman J. M., Th'ng K. H., Park D. S., Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation British Journal of Haematology 1978 40 2 185 195
46. English D., Freezing hematopoietic stem cells Journal of Hematotherapy and Stem Cell Research 2000 9 2 123 125
47. Scheinkonig C., Kappicht S., Kolb H.-J., Schleuning M., Adoption of long-term cultures to evaluate the cryoprotective potential of trehalose for freezing hematopoietic stem cells Bone Marrow Transplantation 2004 34 6 531 536
48. Liseth K., Abrahamsen J. F., Bjorsvik S., Grottebo K., Bruserud O., The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft Cytotherapy 2005 7 4 328 333
49. Vela-Ojeda J., Garcia-Ruiz Esparza M. A., Reyes-Maldonado E., Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation Annals of Hematology 2006 85 2 113 120
50. Liseth K., Ersvr E., Abrahamsen J. F., Nesthus I., Ryningen A., Bruserud O., Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells Transfusion 2009 49 8 1709 1719
51. Unsoeld H., Pircher H., Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7 Journal of Virology 2005 79 7 4510 4513
52. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A., Two subsets of memory T lymphocytes with distinct homing potentials and effector functions Nature 1999 401 6754 708 712
53. Curotto de Lafaille M. A., Lafaille J. J., Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009 30 5 626 635
54. Yu J., Mao H. C., Wei M., CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets Blood 2010 115 2 274 281
55. Rolin J., Sand K. L., Knudsen E., Maghazachi A. A., FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release Cancer Immunology, Immunotherapy 2010 59 4 575 586
56. Maghazachi A. A., Role of chemokines in the biology of natural killer cells. Current Topics in Microbiology and Immunology. In press
57. Miltenyi S., CD 34 + selection: the basic component for graft engineering Oncologist 1997 2 6 410 413
58. Knutson K. L., Disis M. L., Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunology, Immunotherapy 2005 54 8 721 728
59. Warren E. H., Fujii N., Akatsuka Y., Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens Blood 2010 115 19 3869 3878
60. Porrata L. F., Litzow M. R., Markovic S. N., Immune reconstitution after autologous hematopoietic stem cell transplantation Mayo Clinic Proceedings 2001 76 4 407 412
61. Guillaume T., Rubinstein D. B., Symann M., Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation Blood 1998 92 5 1471 1490
62. Yakoub-Agha I., Saule P., Magro L., Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse Biology of Blood and Marrow Transplantation 2009 15 4 496 504
63. Cavazzana-Calvo M., Andre-Schmutz I., Dal Cortivo L., Neven B., Hacein-Bey-Abina S., Fischer A., Immune reconstitution after haematopoietic stem cell transplantation: obstacles and anticipated progress Current Opinion in Immunology 2009 21 5 544 548
64. Talmadge J. E., Reed E., Ino K., Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow Bone Marrow Transplantation 1997 19 2 161 172
65. Mackall C. L., Stein D., Fleisher T. A., Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults Blood 2000 96 2 754 762
66. Cayeux S., Meuer S., Pezzutto A., T-cell ontogeny after autologous bone marrow transplantation: failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4- and CD8+ cells even in the presence of exogeneous IL-2 Blood 1989 74 6 2270 2277
67. Nolte A., Buhmann R., Straka C., Emmerich B., Hallek M., Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation Bone Marrow Transplantation 1998 21 9 909 916
68. Miller R. A., Daley J., Ghalie R., Kaizer H., Clonal analysis of T-cell deficiencies in autotransplant recipients Blood 1991 77 8 1845 1850
69. Dreger P., Viehmann K., von Neuhoff N., Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery Bone Marrow Transplantation 1999 24 2 153 161
70. Galy A., Rudraraju S., Baynes R., Klein J., Recovery of lymphocyte and dendritic cell subsets after autologous CD34+ cell transplantation Bone Marrow Transplantation 2000 25 12 1249 1255
71. Loeffler J., Ok M., Morton O. C., Mezger M., Einsele H., Genetic polymorphisms in the cytokine and chemokine system: Their possible importance in allogeneic stem cell transplantation. Current Topics in Microbiology and Immunology. In press
72. Storek J., Ferrara S., Ku N., Giorgi J. V., Champlin R. E., Saxon A., B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplantation 1993 12 4 387 398
73. Marin G. H., Mendez M. C., Menna M. E., Immune recovery after bone marrow and peripheral blood stem cells transplantation Transplantation Proceedings 1999 31 6 2582 2584
74. Tanaka J., Asaka M., Imamura M., Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia International Journal of Hematology 2005 81 1 6 12
75. Rolin J., Sand K. L., Knudsen E., Maghazachi A. A., FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release Cancer Immunology, Immunotherapy 2010 59 4 575 586
76. Weber G., Karbach J., Kuci S., WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation Leukemia 2009 23 9 1634 1642
77. Smith F. O., Raskind W. H., Fialkow P. J., Bernstein I. D., Cellular biology of acute myelogenous leukemia Journal of Pediatric Hematology and Oncology 1995 17 2 113 122
78. Dao T., Scheinberg D. A., Peptide vaccines for myeloid leukaemias Best Practice and Research: Clinical Haematology 2008 21 3 391 404
79. Scheibenbogen C., Letsch A., Thiel E., CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia Blood 2002 100 6 2132 2137
80. Rezvani K., PR1 vaccination in myeloid malignancies Expert Review of Vaccines 2008 7 7 867 875
81. Rezvani K., Yong A. S. M., Mielke S., Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies Blood 2008 111 1 236 242
82. Smits E. L. J. M., Berneman Z. N., Van Tendeloo V. F. I., Immunotherapy of acute myeloid leukemia: current approaches Oncologist 2009 14 3 240 252
83. Greiner J., Schmitt M., Li L., Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches Blood 2006 108 13 4109 4117
84. Oka Y., Tsuboi A., Taguchi T., Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proceedings of the National Academy of Sciences of the United States of America 2004 101 38 13885 13890
85. Schmitt M., Schmitt A., Rojewski M. T., RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses Blood 2008 111 3 1357 1365
86. Li L., Giannopoulos K., Reinhardt P., Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts International Journal of Oncology 2006 28 4 855 861
87. Lee J.-J., Kook H., Park M.-S., Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation Journal of Clinical Apheresis 2004 19 2 66 70
88. Osada T., Clay T., Hobeika A., Lyerly H. K., Morse M. A., NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity Cancer Immunology, Immunotherapy 2006 55 9 1122 1131
89. Bruserud O., Gjertsen B. T., Foss B., Huang T.-S., New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of AML cellsThe present use in experimental studies and the possible importance for future therapeutic approaches Stem Cells 2001 19 1 1 11
90. Olsnes A. M., Ryningen A., Ersvr E., Bruserud O., In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22 Journal of Interferon and Cytokine Research 2008 28 5 297 310
91. Giannopoulos K., Li L., Bojarska-Junak A., Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia International Journal of Oncology 2006 29 1 95 103
92. Melief C. J. M., Cancer immunotherapy by dendritic cells Immunity 2008 29 3 372 383
93. Banchereau J., Klechevsky E., Schmitt N., Morita R., Palucka K., Ueno H., Harnessing human dendritic cell subsets to design novel vaccines Annals of the New York Academy of Sciences 2009 1174 24 32
94. Um S. J., Choi Y. J., Shin H. J., Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer. In press
95. Chang L. J., Lentiviral vector transduction of dendritic cells for novel vaccine strategies Methods in Molecular Biology 2010 614 161 171
96. Kim H. S., Kim C. H., Park M. Y., Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and surviving into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model. Immunology Letters. In press
97. Winters U., Daayana S., Lear J. T., Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia Clinical Cancer Research 2008 14 16 5292 5299
98. Gausdal G., Gjertsen B. T., McCormack E., Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death Blood 2008 111 5 2866 2877
99. Houot R., Goldstein M. J., Kohrt H. E., Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion Blood 2009 114 16 3431 3438
100. Bruserud O., Ersvr E., Olsnes A., Gjertsen B. T., Anticancer immunotherapy in combination with proapoptotic therapy Current Cancer Drug Targets 2008 8 8 666 675
101. Carella A. M., Pollicardo N., Pungolino E., Mobilization of cytogenetically Normal blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia Leukemia and Lymphoma 1993 9 6 477 483 (Pubitemid 23209532)
102. Wojciechowski J. C., Narasipura S. D., Charles N., Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device British Journal of Haematology 2008 140 6 673 681
103. Huck S. P., Tang S.-C., Andrew K. A., Yang J., Harper J. L., Ronchese F., Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors Cancer Immunology, Immunotherapy 2008 57 1 63 71
104. Houot R., Levy R., Vaccines for lymphomas: idiotype vaccines and beyond Blood Reviews 2009 23 3 137 142
105. Wagner H., The immunogenicity of CpG-antigen conjugates Advanced Drug Delivery Reviews 2009 61 3 243 247
106. Roda J. M., Parihar R., Carson W. E. III, CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells Journal of Immunology 2005 175 3 1619 1627
107. Flaminio M. J., Borges A. S., Nydam D. V., Horohov D. W., Hecker R., Matychak M. B., The effect of CpG-ODN on antigen presenting cells of the foal Journal of Immune Based Therapies and Vaccines 2007 5, article 1
108. Vollmer J., Krieg A. M., Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists Advanced Drug Delivery Reviews 2009 61 3 195 204
109. Ferrantini M., Capone I., Belardelli F., Dendritic cells and cytokines in immune rejection of cancer Cytokine and Growth Factor Reviews 2008 19 1 93 107 (Pubitemid 351200063)
110. Perez-Garcia A., Brunet S., Berlanga J. J., CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy Leukemia 2009 23 3 486 491
111. Reichle A., Hildebrandt G. C., Principles of modular tumor therapy Cancer Microenvironment 2009 2 supplement 1 S227 S237
112. Dimberg A., Chemokines in angiogenesis. Current Topics in Microbiology and Immunology. In press
113. Nakazaki Y., Hase H., Inoue H., Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses Molecular Therapy 2006 14 4 599 606
114. Song S., Liu C., Wang J., Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect Vaccine 2009 27 7 1111 1118
115. Lapteva N., Aldrich M., Weksberg D., Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity Journal of Immunotherapy 2009 32 2 145 156
116. Borroni E. M., Mantovani A., Locati M., Bonecchi R., Chemokine receptors intracellular trafficking. Pharmacology Therapeutics. In press
117. Zang X., Allison J. P., The B7 family and cancer therapy: costimulation and coinhibition Clinical Cancer Research 2007 13 18 5271 5279
118. Rosenblatt J., Wu Z., Vasir B., Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28 Journal of Immunotherapy 2010 33 2 155 166
119. Elgueta R., Benson M. J., de Vries V. C., Wasiuk A., Guo Y., Noelle R. J., Molecular mechanism and function of CD40/CD40L engagement in the immune system Immunological Reviews 2009 229 1 152 172
120. Stauss H. J., Cesco-Gaspere M., Thomas S., Monoclonal t-cell receptors: new reagents for cancer therapy Molecular Therapy 2007 15 10 1744 1750
121. Stauss H. J., Thomas S., Cesco-Gaspere M., WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells Blood Cells, Molecules, and Diseases 2008 40 1 113 116
122. Weaver C. T., Hatton R. D., Mangan P. R., Harrington L. E., IL-17 family cytokines and the expanding diversity of effector T cell lineages Annual Review of Immunology 2007 25 821 852
123. Gaffen S. L., Kramer J. M., Yu J. J., Shen F., The IL-17 cytokine family Vitamins and Hormones 2006 74 255 282
124. Bi Y., Liu G., Yang R., Th17 cell induction and immune regulatory effects Journal of Cellular Physiology 2007 211 2 273 278
125. Kryczek I., Wei S., Zou L., Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment Journal of Immunology 2007 178 11 6730 6733
126. Hirahara N., Nio Y., Sasaki S., Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice Oncology 2001 61 1 79 89
127. Honorati M. C., Neri S., Cattini L., Facchini A., IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis Clinical and Experimental Immunology 2003 133 3 344 349
128. Sakaguchi S., Naturally arising foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self Nature Immunology 2005 6 4 345 352
129. Gallegos A. M., Bevan M. J., Central tolerance: good but imperfect Immunological Reviews 2006 209 290 296
130. Shimizu J., Yamazaki S., Sakaguchi S., Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity Journal of Immunology 1999 163 10 5211 5218
131. Beyer M., Kochanek M., Darabi K., Reduced frequencies and suppressive function of CD4+ CD25 hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine Blood 2005 106 6 2018 2025
132. Ghiringhelli F., Larmonier N., Schmitt E., CD 4 + CD 25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative European Journal of Immunology 2004 34 2 336 344
133. Audia S., Nicolas A., Cathelin D., Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes Clinical and Experimental Immunology 2007 150 3 523 530
134. Qu Y., Zhang B., Zhao L., The effect of immunosuppressive drug rapamycin on regulatory CD4+ CD25+ foxp3+T cells in mice Transplant Immunology 2007 17 3 153 161
135. Garnett C. T., Schlom J., Hodge J. W., Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement Clinical Cancer Research 2008 14 11 3536 3544
136. Szczepanski M. J., Szajnik M., Czystowska M., Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia Clinical Cancer Research 2009 15 10 3325 3332
137. Eisenstein E. M., Williams C. B., The Treg/Th17 cell balance: a new paradigm for autoimmunity Pediatric Research 2009 65 26R 31R